Slides
Page 1
Alembic Pharmaceuticals LimitedInvestor Presentation Q2 FY26
Page 2
Investor Presentation Q2 FY26Alembic Pharmaceuticals Ltd. 2 Safe Harbour StatementThe materials and information presented herein may include forward looking statements , which reflect current expectations, projections, and assumptions. These statements are inherently subject to risks and uncertainties that could cause actual results or outcomes to differ materially from those anticipated.Risks and uncertainties include general industry and market conditions, and general domestic and international economic conditions such as interest rate and currency exchange fluctuations. Risks and uncertainties particularly apply with respect to product related, forward-looking statements. Product risks and uncertainties include but are not limited to technological advances and patents attained by competitors, challenges inherent in new product development including completion of clinical trials; claims and concerns about product safety and efficacy; obtaining regulatory approvals; domestic and foreign healthcare reforms; trend towards managed care and healthcare cost containment, and governmental laws and regulations affecting domestic and foreign operations.Also, for products that are approved, there are manufacturing and marketing risks and uncertainties, which include, but are not limited to the inability to build production capacity to meet demand, unavailability of raw materials, and failure togain market acceptance.
Page 3
Investor Presentation Q2 FY26Alembic Pharmaceuticals Ltd. 3 Quarterly SnapshotIndia Branded BusinessAchieved a 5% YoY growth with quarterly revenues of INR 6.39 billion.US GenericsReported a 21% YoY increase driven by key product launches and market share gains in select therapies. Ex-US GenericsReported a 31% growth YoY . In Ex-US, focus remains on expanding offerings and enhancing market coverage.API15% YoY increase, led by volume growth.+26% YoYKey HighlightsEBIDTA INR 3.24 BnEBIDTA Margin ~17%Revenue INR 19.10 BnR&D 10% of revenue+16% YoY+20% YoYNet Profit INR 1.85 Bn Net Profit Margin 10%+41% YoY
Page 4
Investor Presentation Q2 FY26Alembic Pharmaceuticals Ltd. 4 Revenue Summary Business Q2 FY26 Q2 FY25 Y-o-Y Q1 FY26Q-o-Q H1 FY26 H1 FY25 Y-o-YFormulationsIndia Branded Business 6.39 6.09 5% 5.99 6% 12.38 11.81 5%US Generics 5.66 4.67 21% 5.23 8% 10.89 9.28 17%Ex-US Generics 3.92 2.98 31% 3.28 16% 7.19 5.68 27%API3.14 2.74 15% 2.61 17% 5.75 5.32 8%Total Revenue 19.10 16.48 16% 17.11 10% 36.21 32.10 13%34%30%20%16%H1 FY26 India BrandedBusinessUS GenericsEx-US GenericsAPI INR Bn
Page 5
Investor Presentation Q2 FY26Alembic Pharmaceuticals Ltd. 5 India Branded Business – Performance14.9619.2620.6322.0023.39 FY21 FY22 FY23 FY24 FY25Revenue in Past 5 YearsCAGR: 12% INR Bn>The India Branded Business recorded 5% growth with revenues of INR 6.39 billion for the quarter.>Alembic is ranked 20thin the Indian Pharmaceutical Market (IPM).>13% of the product portfolio is listed under NLEM.>Sales operations include 5,500+ Medical Representatives across 21 marketing divisions.>Holds a 1.3% market share of the Indian Pharma space.*>Four flagship brands have surpassed INR 1 billion in sales.*Source: IQVIA MAT SEP-25 53%51%28%28%19%22%Q2FY25 Q2FY26Revenue Q2 FY26Animal HealthAcuteSpecialty 6.096.3918%10%13%12%10%6%9%22%Sales Mix Q2 FY26Anti InfectiveCough & ColdGynecologyCardiologyGastrologyAnti DiabeticOthersAnimal health
Page 6
Investor Presentation Q2 FY26Alembic Pharmaceuticals Ltd. 6 India Branded Business – Rx Driven RankingsTop Brands with Rank and Market Share * Above market growth is based on the respective molecule group.>Alembic ranks 18th by prescription volume, with a total of 133.2 million prescriptions (MAT Sep 2025). BRANDS Rank Q2FY 26*MS% Q2FY 26*WIKORYL 3 10.4BROZEET-LS 3 6.7ISOFIT 3 5.5ULGEL 3 8.9BLADMIR 3 10.1VELDROP 3 4.6ISOFIT SR 3 15.0BILAMBIC-M 3 6.6CLOFF 4 12.5ETRIK 4 5.0OVIGYN DH 4 10.0TELLZY 5 3.8HARMONI 5 4.8Source: IQVIA MAT June-25 BRANDS Rank Q2FY 26*MS% Q2FY 26*AZITHRAL 1 30.2ALTHROCIN 1 86.3CRINA-NCR 1 29.9ROXID 1 95.2DELTONE 1 54.3GERIJOINT 1 32.1ELATA 1 52.5CETANIL 2 7.0GESTOFIT SR 2 18.1LACTONIC 2 38.5ESTROPLUS 2 47.5TRAVISIGHT 2 15.0UNIGOLIX 2 14.4FREEGO 2 9.0 Driving Overall Prescription Business128.7133.2*Prescriptions (in Mn)MAT Sep-24MAT Sep-250.230.24*Prescribers (in Mn)Sep-24Sep-25
Page 7
Investor Presentation Q2 FY26Alembic Pharmaceuticals Ltd. 7 Q2FY25 Q2FY26 BillionsRevenue Q2 FY2611801380Animal Health Business18412320286035534305 FY21 FY22 FY23 FY24 FY25Revenue in Past 5 YearsCAGR: 24%INR MnGrowth: 17%INR Mn Annual Sales Value INR MnAbove 300 200 - 300 100 - 200 20 - 100No. of Brands5 2 6 20>Alembic operates in the Livestock, Poultry, and Companion Animal segments.>Market leader in Haematinics and Antibiotics with brands such as Sharkoferrol, Moxel , Xceft and Mceft.>The Animal Health division recorded 17% growth in the Quarter.>A well-established portfolio of strong brands continues to drive growth.40%24%16%13%7%Sales Mix Q2 FY26 AntibioticFeed Supplement Tonic Supportive TherapyAntiparasitic
Page 8
Investor Presentation Q2 FY26Alembic Pharmaceuticals Ltd. 8 Q2FY25 Q2FY26Revenue Q2 FY264.675.66US Generics Business21.6316.6615.7217.3019.57FY21 FY22 FY23 FY24 FY25Revenue in Past 5 YearsINR BnGrowth: 21%INR Bn 1543120192Approved ANDAs Oral SolidsDermaOphthalmicInjectableInhalation>Well-established US front-end with a strong customer base.>7 products launched in H1 FY26 with a total of 170 products commercialized in the US now.>Pipeline includes 10+ product launches expected in H2-26.>Products from new facilities will contribute to the future growth.>Evolving portfolio and pipeline in Complex platforms and Specialty divisions.Total 226** Includes 21 Tentative ApprovalsQ2FY26 : 2 ANDA Filings,6 Approvals(including 1 TA).Cumulative : 269 ANDA Filings, 226 approvals and 170 Products Launched so far.
Page 9
Investor Presentation Q2 FY26Alembic Pharmaceuticals Ltd. 9 2.983.92Q2FY25 Q2FY26Revenue Q2 FY26Ex-US Generics Business7.797.758.5210.5212.43 FY21 FY22 FY23 FY24 FY25 Revenue in past 5 YearsCAGR: 12% INR BnGrowth: 31% INR Bn>Achieved 31% YoY growth in Q2, momentum sustained globally through targeted execution and strong customer demand.>Key partnerships active in Europe, Canada, Australia, Brazil, and South Africa.>Future growth will be supported by a robust pipeline of product launches and strategic expansion into new markets.
Page 10
Investor Presentation Q2 FY26Alembic Pharmaceuticals Ltd. 10 API Business9.559.3911.6612.4611.33FY21 FY22 FY23 FY24 FY25 Revenue in past 5 YearsCAGR: 4% INR BnINR Bn>Growth of 15% on annual basis is led by surge in volumes, partially offset by price erosion across the markets.>1 US DMF filed in Q2 FY26. 141 Cumulative DMF filings with the US FDA.>Persistent Focus on cost efficiency to improve the position in competitive markets.>Expect a steady growth for this business.2.743.14Q2FY25 Q2FY26Revenue Q2 FY26Growth: 15%
Page 11
Investor Presentation Q2 FY26Alembic Pharmaceuticals Ltd. 11 R&DContinued investment in building product pipelinesR&D CapabilitiesFormulation & API: Vadodara and Hyderabad Bio Centre :VadodaraResult: Rising ANDA-accelerated filings and approvalsChange in total approvals (Final + Tentative) during the FY6.7 8.4 7.2 4.8 5.2 14.0%15.8%12.8%7.6%7.8%FY21 FY22 FY23 FY24 FY25R&D SpendR&D % of sales2923201582021241829FY21 FY22 FY23 FY24 FY25FilingApproval Dosage Form-wise ANDA Approval and Launch – H1 FY26INR BnR&D Spent H1-FY’26INR Bn7121 142102468OSD OSD-Onco Injectables Injectables-Onco Opthalmology DermaApprovalLaunchedApproved ANDA Includes 1 Tentative approvals; Q2FY26 - 12.473.3222.22.42.62.833.23.4H1'FY 25 H1'FY 26
Page 12
Investor Presentation Q2 FY26Alembic Pharmaceuticals Ltd. 12 Q2 Financials Summary – Profit & Loss statementINR BnParticulars Q-2 FY25 Q-1 FY26 Q-2 FY26 YoY(%) QoQ(%) H-1 FY 25 H-1 FY 26 YoY(%)Revenue from Operations 16.48 17.11 19.10 16% 12% 32.10 36.21 13%Other Income 0.17 0.07 0.07 0.19 0.13 -29%Total Income 16.65 17.17 19.1715% 12%32.29 36.3413%Material Consumption 4.29 4.07 5.16 20% 27% 8.23 9.23 12%Employee benefits expense 3.91 4.23 4.38 12% 3% 7.71 8.60 12%Finance Costs 0.19 0.24 0.24 29% 3% 0.32 0.48 49%Depreciation & Amortization Expense 0.71 0.74 0.76 8% 3% 1.40 1.50 7%Other Expenses 5.88 5.99 6.41 9% 7% 11.39 12.40 9%Total Expenses14.98 15.27 16.95 13% 11% 29.05 32.21 11%Profit before Share of Profit / (Loss) of Associates 1.671.912.2233%17%3.234.1328%Share of Profit / (Loss) of Associates & Joint Ventures 0.01 0.00 0.01 0.01 0.01Exceptional Iteam 0.13 0.00 0.00 0.13 0.00Profit Before Tax 1.80 1.90 2.2424% 18%3.37 4.1423%Tax Expense 0.27 0.36 0.40 0.50 0.76Profit for the Period 1.53 1.54 1.8420% 20%2.88 3.3717%Non-controlling interests 0.00 0.01 0.01 0.00 0.02Profit for the Period attributable to shareholders1.531.541.8520%20%2.883.3918%Gross Margin74% 76% 73% 74% 74%EBIDTA Margin16% 17% 17% 16% 17%PBT Margin11% 11% 12% 11% 11%PAT Margin9% 9% 10% 9% 9%R&D Expenses as % Revenue8% 8% 10% 8% 9%
Page 13
Investor Presentation Q2 FY26Alembic Pharmaceuticals Ltd. 13 Q2 Financials Summary – Balance sheetINR BnParticularsAs at 31st March, 2025As at 30th September, 2025Non-current assetsProperty, plant and equipment25.24 26.12Capital work-in-progress8.37 9.03Other Intangible assets 0.00 2.22Financial Assets 1.27 1.29Deferred tax assets1.66 1.65Other non-current assets0.31 0.16Current assetsInventories22.88 25.41Trade receivables14.00 13.14Cash and cash equivalents0.83 1.34Bank balances other than cash and cash equivalents0.07 0.09Other financial assets0.12 0.12Current Tax Assets0.11 0.09Other current assets2.87 3.3040.88 43.50TOTAL - ASSETS77.73 83.97EquityEquity Share capital0.39 0.39Other Equity51.52 52.80Equity attributable to owners of the Company51.91 53.19Non-controlling interests-0.01 -0.03Total Equity51.90 53.16Non-current liabilitiesBorrowings- 0.40Lease liabilities0.47 0.44Provisions1.24 0.98Other Non current Liability0.00 1.69Current liabilitiesBorrowings11.96 13.74Lease liabilities0.15 0.31Trade payables8.80 8.87Other financial liabilities1.50 2.04Other current liabilities0.67 0.62Provisions0.86 1.14Current Tax Liabilities0.19 0.5724.12 27.30TOTAL - EQUITY AND LIABILITIES77.73 83.97
Page 14
Investor Presentation Q2 FY26Alembic Pharmaceuticals Ltd. 14 Yearly Financials #Note : FY22 & FY23 numbers are without considering one-time impact of Aleor write off for better comparison20%14% #15% #16%FY22 FY23 FY24 FY25EBIDTA margin %53.0656.5362.2966.72FY22 FY23 FY24 FY25Revenue4.674.123.455.75FY22 FY23 FY24 FY25Capex10.537.79 #9.61 #10.53FY22 FY23 FY24 FY25EBIDTA25% *14%*#15% *#16%*#FY22 FY23 FY24 FY25ROCE %6.654.97 #6.165.84FY22 FY23 FY24 FY25Net ProfitINR Bn * Capital excludes New Projects
Page 15
Investor Presentation Q2 FY26Alembic Pharmaceuticals Ltd. 15 Sustainability>A l e m b i c ’ s E S G T a r g e t sNet Zero by 2050•63% GHG Emission reduction by 2034•90% GHG Emission reduction by 2050(Approved by SBTi)Water Neutrality by 202750,000 trees by 2027•We are one of the 10 Indian Pharma companies with approved targets under SBTi•Commissioned 24 MW solar park at Bhatpur, Vadodara•20% Reduction in specific water consumption (KL/MT)•81% treated water recycled•Developed 112 recharge wells•Planted 25,000+ trees•16% Reduction in landfill waste•Improved ratings in carbon disclosure projectE n v i r o n m e n t •Zero fatality•Great place to work certification for 3rdconsecutive year•7% increase in safety observations•2,44,460 beneficiaries impacted through CSR InitiativesS o c i a l•Implemented supplier Code of Conduct and the sustainable procurement policy•27% critical vendors assessed against the ESG criteria•Initiated a comprehensive organizational risk assessmentG o v e r n a n c e
Page 16
Investor Presentation Q2 FY26Alembic Pharmaceuticals Ltd. Company Overview
Page 17
Investor Presentation Q2 FY26Alembic Pharmaceuticals Ltd. 17 Company at a GlanceANDA Filings269 (Sep 30,2025)R&D Centers2Manufacturing Facilities10Brands207Field Force5,500+Net Zero Target2050Products in the USA170Team Size16,500+MissionImprove Healthcare with innovation, commitment and TrustPrescribers in India2,44,000
Page 18
Investor Presentation Q2 FY26Alembic Pharmaceuticals Ltd. 18 Value Proposition Developing a specialty drug pipeline for IndiaExploring opportunities in InjectablesSupplying APIs to 60+ countries globallyConsistent, high dividend payoutRanks 20thin the Indian formulations marketEstablished presence in Chile & UAEExpanding product portfolio in the USAStrengthening presence in Canada, South Africa, LATAM & Middle East
Page 19
Investor Presentation Q2 FY26Alembic Pharmaceuticals Ltd. 19 The Journey1907Established by the Amin Family2006FDA-approved API facility2007Acquired Dabur’s Indian Cardiology, GI & Gynecology brands2008FDA-approved Formulation facility2009Multiple divisions to address chronic therapies launched2013Launched first NDA with a partner. Commenced filing in the EU, Australia & Brazil2010Pharmaceutical business demerged from the Alembic Group2015Launched Aripiprazole. Established US front-end transition to direct marketing 2012Formed a JV, Rhizen , for NCE Research2013Formed a JV, Aleor , for dermatology portfolio2019Azithral crossed Rs . 250 crore mark as per ORG IMS, MAT Dec 20192022Azithral ranked 16thhighest selling brand. Aleor Dermaceuticalsmerged with Alembic Pharma2023Started commercialization of products from Injectablesand Oncology facilities2025Indore facility Commissioned & Acquired Utility Therapeutics Limited
Page 20
Investor Presentation Q2 FY26Alembic Pharmaceuticals Ltd. 20 Product brand logo Robust InfrastructureF2 - Panelav F3 - Karkhadi Dosage FormLast USFDA AuditInternational GenericsF1 - Panelav General Oral Solids July’24F2 - Panelav Oncology Oral Solids Mar’24Oncology Injectables Oct’24F3 - Karkhadi General InjectablesOphthalmicMar’23F4 - Jarod General Oral Solids Nov’24F5 - Karkhadi Various derma forms Mar’23APIAPI I & II – Panelav May’25*API III - Karkhadi Mar’25 F4 - Jarod F5 - Karkhadi * API I & II : USFDA Audit cleared. EIR Received.
Page 21
2ndFloor, Prime Corporate Park Sahar Road, Andheri East Mumbai 400 099www.alembicphamaceuticals.com Thank YouFor further queries, please contact:Mr. Ajay Desaiajay.desai@alembic.co.in022-6695 3681Investor Relations AdvisorsAdfactors PR Pvt. Ltd.Snighter Albuquerquesnighter.a@adfactorspr.comDarshan Mankaddarshan.mankad@adfactorspr.com